Advancing Preeclampsia Risk Assessment: Integrating the sFlt-1/PlGF Ratio into Clinical Practice

Preeclampsia is a leading cause of maternal and fetal morbidity and mortality, yet traditional diagnostic approaches are often non‑specific and limited in predicting disease progression.¹ In 2025, the U.S. FDA cleared the Elecsys® sFlt‑1/PlGF ratio to help assess the likelihood of developing preeclampsia with severe features within two weeks, based on the multicenter PRAECIS trial, and ACOG now recognizes this ratio as a complementary risk‑stratification tool for hospitalized patients between 23–35 weeks of gestation.

This webinar brings together clinical and laboratory experts to share how the sFlt-1/PlGF ratio is being integrated into real-world practice. Attendees will hear perspectives on clinical utility, review key evidence, and gain practical insights from implementation experiences.

Who should attend: Maternal-fetal medicine specialists, OB/GYNs, and laboratorians

What You’ll Gain:

• Insight into the clinical evidence supporting the sFlt-1/PlGF ratio for short-term preeclampsia risk assessment and its role in practice
• Practical understanding of how to interpret the Elecsys sFlt-1/PlGF ratio to help identify severe preeclampsia and potential adverse outcomes
• Strategies for integrating angiogenic biomarkers with standard assessments to enhance patient monitoring, management, and resource optimization

Join us to learn how these advances can support more informed, timely decision-making in preeclampsia care—and how to begin applying them within your institution.